



Cancer Immunotherapy and Vaccines Research

Guest Editors:

Dr. Luigi Buonaguro

Innovative Immunological
Models Unit, National Cancer
Institute - IRCCS "Pascale", Via
Mariano, Semmola, 52, 80131
Napoli, Italy

Dr. Maria Tagliamonte

Laboratory of Innovative
Immunological Models, Istituto
Nazionale per lo Studio e la Cura
dei Tumori, "Fondazione
Pascale"-IRCCS, 80131 Naples,
Italy

Deadline for manuscript
submissions:

closed (28 February 2022)

Message from the Guest Editors

Dear colleagues,

Cancer vaccines are one of the main pillars of the cancer immunotherapy even in the era of checkpoint inhibitors. Indeed, although the latter have completely changed the scenario of cancer treatment, several patients do not benefit from them. However, the cancer vaccine field is still a work in progress field because an effective strategy has not been developed yet. The topic of the special issue will cover all the aspects involved in the vaccine research and development (i.e. identification of optimal target antigens, formulations, delivery strategies, adjuvants, combination with other immunomodulatory approaches).

Dr. Luigi Buonaguro

Dr. Maria Tagliamonte

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com